Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
July 9, 2019
Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights
Sangeetha Venugopal, Selena Zhou, Siraj M El Jamal, et al.
Clinical Case Reports
|
June 8, 2017
Ibrutinib-induced severe liver injury
Amara G Nandikolla, Olga Derman, Deborah Nautsch, et al.
Thrombosis Research
|
August 28, 2020
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
Leonard Naymagon, Nicole Zubizarreta, Jonathan Feld, et al.
Blood Cancer Journal
|
January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
Sangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
American Journal of Hematology
|
September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia
Sangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Cancer
|
December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia
Alexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Cancer
|
June 28, 2021
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy
Sangeetha Venugopal, Mahran Shoukier, Marina Konopleva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
The Lancet. Haematology
|
February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Alex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.
Journal of Hematology & Oncology
|
January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
Nicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Clinical Lymphoma, Myeloma & Leukemia
|
July 9, 2019
Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights
Sangeetha Venugopal, Selena Zhou, Siraj M El Jamal, et al.
Clinical Case Reports
|
June 8, 2017
Ibrutinib-induced severe liver injury
Amara G Nandikolla, Olga Derman, Deborah Nautsch, et al.
Thrombosis Research
|
August 28, 2020
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
Leonard Naymagon, Nicole Zubizarreta, Jonathan Feld, et al.
Blood Cancer Journal
|
January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
Sangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
American Journal of Hematology
|
September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia
Sangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Cancer
|
December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia
Alexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Cancer
|
June 28, 2021
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy
Sangeetha Venugopal, Mahran Shoukier, Marina Konopleva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
The Lancet. Haematology
|
February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
Alex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.
Journal of Hematology & Oncology
|
January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure
Nicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.
Page
of 4